Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06707584

Role of MRI in Breast Cancer Subtypes

efficacy of MRI in detection of breast cancer molecular subtypes instead of biopsy and immunohistochemistry

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Sex eligibility

All sexes

Study type

Observational

About this study

2.4.4 -Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …): Patient with breast cancer (malignant breast mass) will do MRI breast and molecular subtypes will be assessed

MRI imaging studies will performed on a 1.5 T scanner , The patient is placed in the prone position with both breasts placed adequately in a double breast coil (four-channel phased array coil), MRI sequences are:

  • Axial T1WI. 2. Axial T2WI. 3. Axial STIR. 4. DCE-MRI with post-processing subtraction images 5- Axial DWI at b value( 0, 400, 800 and 1000 mm^2 per second) and ADC map will performed 6. MRI spectroscopy MRI acquisition protocol MRI protocols includes
  • Axial T2-weighted fast spin echo sequence: TR=3840 ms, TE=81 ms, slice thickness=3.5 mm, and matrix=448×448.
  • Coronal T2-weighted fast spin echo sequence: TR=3840 ms, TE=81 ms, slice thickness=3.5 mm, and matrix=448×448.s
  • Short tau inversion recovery - axial: TR=8540 ms, TE=59 ms, TI=170 ms, slice thickness=3.5 mm, and matrix=320×314.4.
  • The standard dynamic protocol commenced with a coronal three-dimensional rapid Field echo (thrive) sense non-enhanced T1-weighted sequence.
  • A gadolinium containing contrast was administered at a dose of 0.2 ml/ kg by power injection at a speed of 2.0 ml/s and flushed with 20 ml of saline solution at the same rate.
  • Dynamic imaging was then done in five consecutive series at 90-s intervals. Standard subtraction images were obtained by subtracting precontract images from the early peak postcontrast image.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

a. patients with breast cancer confirmed by histopathology,

Exclusion criteria

  • breast implants
  • general Contraindication of MRI as claustrophobia

Treatment and study plan

Primary outcomes

  1. accuracy of MRI in breast cancer subtyping

    Time frame: 5 years

    To investigate the diagnostic accuracy of dynamic post contrast imaging MRI in evaluation of breast cancer molecular subtypes and DWI and ADC in detection of breast cancer molecular subtypes

Sponsors and collaborators

Lead sponsor

Lamiaa Gomaa Ahmed Elsayed

Other

Registry information

Official study title

Role of MRI in Detection of Breast Cancer Molecular Subtypes in Correlation With Immunohistochemistry Results

Acronym: MRI

Important dates

Study start
2025
Primary completion
2029
Study completion
2030
First posted
Nov 27, 2024
Registry last updated
Nov 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.